Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today provided a financial update, reiterating full ...

Halozyme (NASDAQ:HALO) has raised its financial guidance estimates for 2025 based on expected strong sales of products ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will host an Investor Conference Call on Wednesday ...

H.C. Wainwright raised the firm’s price target on Halozyme (HALO) to $70 from $68 and keeps a Buy rating on the shares. The company has strong ...

Piper Sandler raised the firm’s price target on Halozyme (HALO) to $53 from $52 and keeps a Neutral rating on the shares after maintaining FY24 ...

Wells Fargo has recently reduced Halozyme Therapeutics, Inc. (HALO) stock to Equal Weight rating, as announced on October 7, 2024, according to Finviz. Earlier, on September 19, 2024, JP Morgan had ...

Shares of Sana Biotechnology SANA skyrocketed 151.5% in the past week after the company announced positive initial results ...

US biotech Halozyme Therapeutics has withdrawn its offer to acquire Evotec, saying that the German company had been "unwilling to engage with us to explore a potential combination." Halozyme made ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...